Add like
Add dislike
Add to saved papers

Mechanism of dioscin ameliorating renal fibrosis through NF‑κB signaling pathway‑mediated inflammatory response.

Dioscin (DIS) is a natural compound derived from Chinese herbal medicine. In recent years, multiple studies have reported that DIS has immunoregulation, anti‑fibrosis, anti‑inflammation, anti‑viral and anti‑tumor effects. However, the mechanism by which DIS ameliorates renal fibrosis and inflammation remains to be elucidated. The aim of the present study was to investigate the role of DIS in renal fibrosis and inflammation and to explore its underlying mechanism. It used network pharmacology to predict the targets of DIS for the treatment of renal interstitial fibrosis. The present study was performed using unilateral ureteral obstruction mice and HK‑2 cells in vivo and in vitro . The mice were treated with different doses of DIS. Kidney tissues were collected for histopathology staining, western blotting, immunohistochemistry staining and reverse transcription‑quantitative (RT‑q) PCR. TGF‑β1 (2 ng/ml) was used to induce renal fibrosis in the cells. Then, cells were respectively treated with DIS (3.125, 6.25, 12.5 µM) and Bay11‑7082 (an inhibitor of NF‑κB p65 nuclear transcription, 1 µM) for another 24 h. The expressions of inflammatory factors and NF‑κB pathway proteins were detected by immunofluorescence, ELISA, western blotting and RT‑qPCR. DIS alleviated renal injury in the UUO mice. Mechanistically, DIS not only decreased the expressions of inflammatory factors including IL‑1β, NOD‑like receptor thermal protein domain associated protein 3, monocyte chemotactic protein 1, IL‑6, TNF‑α and IL‑18 but also reduced the level of phosphorylation of NF‑κB p65 in vivo and in vitro , which was similar to the impact of Bay11‑7082. DIS ameliorated renal fibrosis by inhibiting the NF‑κB signaling pathway‑mediated inflammatory response, which may be a therapeutic pathway for delaying chronic kidney disease.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app